Switching from Combivir[CBV] (AZT/3TC) to Truvada [TVD] (Tenofovir DF/FTC) Maintains Viral Suppression, Prevents and Reverses Limb Fat Loss, and Improves Biochemical Parameters: Results of a 48 Week Randomised Study by Martin Fisher given during the 11th European AIDS Conference / EACS powered by - MULTIWEBCAST

11th European AIDS Conference / EACS

LIST OF PRESENTATIONS/COURSES

OTHER WEBCASTS

Webcasted Presentation

BROWSE:

ALL PRESENTATIONS/COURSES

SPEAKERS

PPT SLIDES

VIDEO PODCASTS

Switching from Combivir[CBV] (AZT/3TC) to Truvada [TVD] (Tenofovir DF/FTC) Maintains Viral Suppression, Prevents and Reverses Limb Fat Loss, and Improves Biochemical Parameters: Results of a 48 Week Randomised Study

Martin Fisher

United Kingdom

Disclosure : Gilead Sciences Study, Granta Park, Abington, CAMBS CB21 GGT UK

[More] [Less]

PRESENTATION

16 slide(s) – 00:12:04 – English – 2007-10-25

Extra Features Available

VIDEO PODCAST

SLIDE LIBRARY

Rate & Comment

A A A


Rate:
Please let us know how useful this content was for you and feel free to write your comments below.

Disclaimer ^{AMENDED ON January 29, 2009} | Technical Support

USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.

Search’n Build™